Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Alembic Pharmaceuticals Ltd.
Change Company   
BSE Code 533573
ISIN Demat INE901L01018
Book Value 255.98
NSE Code APLLTD
Dividend Yield % 1.04
Market Cap 207374.10
P/E 26.69
EPS 39.53
Face Value 2  
20-Dec-2024 Alembic Pharmaceuticals gets USFDA’s final approv...
11-Dec-2024 Alembic Pharmaceuticals completes ANVISA GMP audi...
11-Dec-2024 Alembic Pharmaceuticals informs about updates
04-Dec-2024 Alembic Pharma gets USFDA’s tentative nod for Olo...
02-Dec-2024 Alembic Pharmaceuticals informs about details of ...
25-Nov-2024 USFDA completes inspection at Alembic Pharmaceuti...
12-Nov-2024 Alembic Pharma gets USFDA’s final approval for Iv...
11-Nov-2024 Alembic Pharma gets final nod for Diltiazem Hydro...
11-Nov-2024 Alembic Pharmaceuticals informs about press rele...
23-Oct-2024 Alembic Pharmaceuticals informs about loss of sha...
21-Oct-2024 Alembic Pharma gets USFDA approval for Diltiazem ...
21-Oct-2024 Alembic Pharma soars on getting USFDA approval fo...
09-Oct-2024 USFDA completes inspection at Alembic Pharmaceuti...
09-Oct-2024 Alembic Pharmaceuticals informs about disclosure
04-Oct-2024 Alembic Pharmaceuticals gets final nod for Alcaft...
Page 1 of 4
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA
Publishing of investor charter information | Annexure A – Investor charter of brokers |
Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.